BioSpace News Archive

Policy

Incyte Claims Flexus Lured Away CSO and Its IDO Secrets, Then Sold Itself to Bristol-Myers in $1.25B Deal

Incyte has levelled charges of stealing company secrets against the founders of Flexus Biosciences over the hiring of Incyte’s former CSO who had access to Incyte’s scientific research.

October 16, 2017

·

2 min read

·

Alex Keown

Drug Development

Eli Lilly Release: Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown To Benefit In New CYRAMZA (Ramucirumab) Phase III Subgroup Analysis

New subgroup analysis from Eli Lilly’s Phase 3 REVEL trial of CYRAMZA (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18th World Conference on Lung Cancer (WCLC).

October 16, 2017

·

29 min read

Lone Star Bio

Trievr To Provide Major Pharmas With Request Management Platform To Meet New FDA Quality Metrics Requirements

Trievr today announced that three of the top 10 major pharmaceutical companies have signed with Trievr to help facilitate and simplify the new FDA Quality Metrics (QM) Requirements.

October 16, 2017

·

2 min read

Pharm Country

MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC

MEBIAS Discovery, an emerging leader in the field of biased agonism G-Protein Coupled Receptor (GPCR) drug discovery, presented preclinical data on two novel drug candidates at the Academic Drug Discovery Consortium on October 12, 2017.

October 16, 2017

·

4 min read

Biotech Beach

Vitality Biopharma Announces Publication Of International PCT Patent Filing

Vitality Biopharma announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.

October 16, 2017

·

3 min read

Business

Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy

Aimmune Therapeutics, Inc., today announced a clinical collaboration with Regeneron and its strategic alliance collaborator Sanofi to study AR101 treatment with adjunctive dupilumab in peanut-allergic patients in a Phase 2 clinical trial.

October 16, 2017

·

7 min read

Drug Development

Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients

Halozyme today announced initiation of a clinical trial evaluating its investigational new drug PEGPH20 with atezolizumab (TECENTRIQ).

October 16, 2017

·

5 min read

Policy

Eloxx Pharmaceuticals Announces Expansion Of Intellectual Property Estate For ELX-02 With Newly Granted Patent In Europe

Sevion Therapeutics and Eloxx Pharmaceuticals announcedd that the European Patent Office (EPO) has granted a patent covering the Company’s lead product candidate, ELX-02, as well as other proprietary compounds.

October 16, 2017

·

3 min read

Enzyvant Initiates Farber Disease Natural History Study

Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced the initiation of the Farber Disease Natural History Study.

October 16, 2017

·

3 min read

Biotech Bay

Genentech To Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data In Relapsing And Primary Progressive Forms Of Multiple Sclerosis At ECTRIMS

Genentech announced today that new data on OCREVUS (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis.

October 16, 2017

·

15 min read